It	O	0,2
is	O	3,5
customary	O	6,15
to	O	16,18
divide	O	19,25
Lyme	B-KP	26,30
disease	I-KP	31,38
into	O	39,43
three	O	44,49
stages	O	50,56
.	O	56,57

The	O	58,61
“	O	62,63
primary	B-KP	63,70
lesion	I-KP	71,77
”	O	77,78
or	O	79,81
early	O	82,87
localized	O	88,97
stage	O	98,103
occurs	O	104,110
at	O	111,113
the	O	114,117
site	O	118,122
of	O	123,125
Borrelia	B-KP	126,134
inoculation	I-KP	135,146
.	O	146,147

The	O	148,151
infection	O	152,161
is	O	162,164
manifest	O	165,173
as	O	174,176
erythema	B-KP	177,185
migrans	I-KP	186,193
(	O	194,195
migrating	O	195,204
redness	O	205,212
)	O	212,213
,	O	213,214
an	O	215,217
erythematous	B-KP	218,230
papule	I-KP	231,237
that	O	238,242
expands	O	243,250
centrifugally	O	251,264
over	O	265,269
days	O	270,274
to	O	275,277
become	O	278,284
a	O	285,286
plaque	B-KP	287,293
,	O	293,294
with	O	295,299
or	O	300,302
without	O	303,310
central	O	311,318
clearing	O	319,327
(	O	328,329
Fig	O	329,332
.	O	332,333

2	O	334,335
)	O	335,336
.	O	336,337

With	O	338,342
the	O	343,346
development	O	347,358
of	O	359,361
EM	B-KP	362,364
,	O	364,365
the	O	366,369
patient	O	370,377
may	O	378,381
also	O	382,386
have	O	387,391
constitutional	O	392,406
symptoms	O	407,415
such	O	416,420
as	O	421,423
fever	B-KP	424,429
,	O	429,430
malaise	B-KP	431,438
,	O	438,439
and	O	440,443
headache	B-KP	444,452
.	O	452,453

The	O	454,457
skin	B-KP	458,462
lesion	I-KP	463,469
may	O	470,473
have	O	474,478
localized	O	479,488
pain	O	489,493
or	O	494,496
pruritus	B-KP	497,505
,	O	505,506
and	O	507,510
regional	B-KP	511,519
lymphadenopathy	I-KP	520,535
may	O	536,539
develop	O	540,547
.	O	547,548

In	O	549,551
~	O	552,553
20	O	553,555
%	O	555,556
of	O	557,559
untreated	O	560,569
subjects	O	570,578
,	O	578,579
this	O	580,584
early	O	585,590
stage	O	591,596
with	O	597,601
EM	B-KP	602,604
remains	O	605,612
the	O	613,616
only	O	617,621
manifestation	O	622,635
of	O	636,638
Lyme	B-KP	639,643
disease	I-KP	644,651
.	O	651,652

In	O	653,655
the	O	656,659
first	O	660,665
few	O	666,669
weeks	O	670,675
after	O	676,681
infection	O	682,691
,	O	691,692
spirochetes	B-KP	693,704
can	O	705,708
be	O	709,711
cultured	O	712,720
from	O	721,725
blood	O	726,731
of	O	732,734
up	O	735,737
to	O	738,740
45	O	741,743
%	O	743,744
of	O	745,747
American	O	748,756
patients	O	757,765
,	O	765,766
indicating	O	767,777
that	O	778,782
they	O	783,787
disseminate	O	788,799
via	O	800,803
the	O	804,807
bloodstream	O	808,819
to	O	820,822
other	O	823,828
tissues	O	829,836
[	O	837,838
101-103	O	838,845
]	O	845,846
.	O	846,847

Note	O	848,852
,	O	852,853
however	O	854,861
,	O	861,862
that	O	863,867
culture	O	868,875
isolation	O	876,885
from	O	886,890
blood	O	891,896
is	O	897,899
much	O	900,904
less	O	905,909
frequently	O	910,920
achieved	O	921,929
in	O	930,932
European	O	933,941
patients	O	942,950
(0.7-7.7%)	O	951,961
[	O	962,963
104-106	O	963,970
]	O	970,971
,	O	971,972
possibly	O	973,981
suggesting	O	982,992
other	O	993,998
routes	O	999,1005
of	O	1006,1008
dissemination	O	1009,1022
.	O	1022,1023

The	O	1024,1027
“	O	1028,1029
secondary	B-KP	1029,1038
lesions	I-KP	1039,1046
”	O	1046,1047
of	O	1048,1050
Borrelia	B-KP	1051,1059
infection	I-KP	1060,1069
,	O	1069,1070
the	O	1071,1074
early	O	1075,1080
disseminated	O	1081,1093
stage	O	1094,1099
,	O	1099,1100
comprises	O	1101,1110
multiple	O	1111,1119
EM	B-KP	1120,1122
lesions	I-KP	1123,1130
,	O	1130,1131
widespread	O	1132,1142
erythematous	B-KP	1143,1155
plaques	I-KP	1156,1163
that	O	1164,1168
are	O	1169,1172
smaller	O	1173,1180
but	O	1181,1184
morphologically	O	1185,1200
similar	O	1201,1208
to	O	1209,1211
the	O	1212,1215
initial	O	1216,1223
lesion	B-KP	1224,1230
.	O	1230,1231

The	O	1232,1235
early	O	1236,1241
disseminated	O	1242,1254
stage	O	1255,1260
may	O	1261,1264
also	O	1265,1269
be	O	1270,1272
associated	O	1273,1283
with	O	1284,1288
Lyme	B-KP	1289,1293
neuroborreliosis	I-KP	1294,1310
(	O	1311,1312
LNB	B-KP	1312,1315
)	O	1315,1316
,	O	1316,1317
and	O	1318,1321
carditis	B-KP	1322,1330
.	O	1330,1331

European	O	1332,1340
patients	O	1341,1349
may	O	1350,1353
also	O	1354,1358
develop	O	1359,1366
a	O	1367,1368
skin	B-KP	1369,1373
lesion	I-KP	1374,1380
called	O	1381,1387
borrelial	B-KP	1388,1397
lymphocytoma	I-KP	1398,1410
during	O	1411,1417
this	O	1418,1422
stage	O	1423,1428
(	O	1429,1430
Fig	O	1430,1433
.	O	1433,1434

3	O	1435,1436
)	O	1436,1437
.	O	1437,1438

The	O	1439,1442
“	O	1443,1444
tertiary	B-KP	1444,1452
skin	I-KP	1453,1457
lesion	I-KP	1458,1464
”	O	1464,1465
of	O	1466,1468
this	O	1469,1473
infection	O	1474,1483
,	O	1483,1484
identified	O	1485,1495
for	O	1496,1499
decades	O	1500,1507
before	O	1508,1514
the	O	1515,1518
association	O	1519,1530
with	O	1531,1535
Borreliawas	B-KP	1536,1547
known	O	1548,1553
,	O	1553,1554
is	O	1555,1557
acrodermatitis	B-KP	1558,1572
chronic	I-KP	1573,1580
atrophicans	I-KP	1581,1592
,	O	1592,1593
a	O	1594,1595
focal	O	1596,1601
area	O	1602,1606
of	O	1607,1609
atrophic	B-KP	1610,1618
skin	I-KP	1619,1623
usually	O	1624,1631
involving	O	1632,1641
an	O	1642,1644
extremity	O	1645,1654
.	O	1654,1655

Acordermatitis	B-KP	1656,1670
chronica	I-KP	1671,1679
atrophicans	I-KP	1680,1691
(	O	1692,1693
ACA	B-KP	1693,1696
)	O	1696,1697
is	O	1698,1700
primarily	O	1701,1710
found	O	1711,1716
in	O	1717,1719
Europe	O	1720,1726
,	O	1726,1727
and	O	1728,1731
is	O	1732,1734
most	O	1735,1739
commonly	O	1740,1748
associated	O	1749,1759
with	O	1760,1764
the	O	1765,1768
late	O	1769,1773
disseminated	O	1774,1786
stage	O	1787,1792
,	O	1792,1793
which	O	1794,1799
can	O	1800,1803
also	O	1804,1808
include	O	1809,1816
late	O	1817,1821
neurological	O	1822,1834
manifestations	O	1835,1849
.	O	1849,1850

Although	O	1851,1859
LA	B-KP	1860,1862
can	O	1863,1866
occur	O	1867,1872
during	O	1873,1879
the	O	1880,1883
early	O	1884,1889
disseminated	O	1890,1902
stage	O	1903,1908
,	O	1908,1909
it	O	1910,1912
is	O	1913,1915
more	O	1916,1920
commonly	O	1921,1929
observed	O	1930,1938
during	O	1939,1945
the	O	1946,1949
late	O	1950,1954
disseminated	O	1955,1967
stage	O	1968,1973
.	O	1973,1974

